FDA Slacks on Hemp Rules: Feds Miss Big Congressional Deadline for Cannabinoid Clarity

The FDA is dragging its feet again, missing a key deadline to clarify hemp regulations and cannabinoid labeling. While the feds stall, the states are busy. Hawaii is looking to fast-track medical access, and Pittsburgh is demanding full adult-use legalization by 2026. On the flip side, an Arizona senator is trying to criminalize "excessive" cannabis odor—a clear step backward for the community. Meanwhile, Missouri is facing an audit over licensing "deficiencies," and South Dakota is modernizing with digital patient cards.

This mixed bag of news highlights the ongoing tug-of-war between progress and outdated stigmas. For regular tokers, the push for faster medical access and digital cards means less red tape and better accessibility. However, the FDA's silence and petty odor bills in Arizona remind us that we still need to stay loud to protect our rights. Faster licensing and clear federal guidance are the real keys to a stable, fair market that prioritizes patients and enthusiasts over bureaucracy.